Advertisement

Document › Details
VectivBio Holding AG. (4/13/21). "Press Release: VectivBio Announces Closing of $146.6 Million Initial Public Offering". Basel.
![]() |
Region | United States (USA) |
![]() |
Organisation | VectivBio Holding AG (Nasdaq: VECT) |
Group | VectivBio (Group) | |
Organisation 2 | Nasdaq Global Market | |
Group | Nasdaq OMX (Group) | |
![]() |
Product | DRUGS, ORPHAN |
Product 2 | investment banking | |
![]() |
Index term | VectivBio–SEVERAL: investment, 202104 IPO $127.5m+$19.125m with 7.5m+1.125m ordinary shares at $17/share at Nasdaq Global Market |
![]() |
Person | Morrell, Graham (Paddock Circle Advisors 201808) |
VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the closing of its initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase an additional 1,125,000 ordinary shares, at a public offering price of $17.00 per share. The gross proceeds from the offering were approximately $146.6 million. Vectiv’s ordinary shares began trading on the Nasdaq Global Market under the ticker symbol “VECT” on April 9, 2021. All of the ordinary shares were offered by Vectiv.
BofA Securities, SVB Leerink and Credit Suisse acted as joint book-running managers for the offering. LifeSci Capital also acted as an underwriter for the offering.
The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from: may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by email at dg.prospectus_requests@bofa.com; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6105 or by email at syndicate@svbleerink.com; or Credit Suisse Securities (USA) LLC Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on April 8, 2021. Copies of the registration statement can be accessed by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About VectivBio
VectivBio (Nasdaq:VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).
Investors
Graham Morrell
graham.morrell@vectivbio.com
Media
Morgan Warners
+1 202 295 0124
morgan.warners@fgh.com
Record changed: 2022-05-07 |
Advertisement
![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg)
More documents for VectivBio (Group)
- [1] VectivBio Holding AG. (3/30/22). "Press Release: VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts". Basel....
- [2] VectivBio Holding AG. (9/21/21). "Press Release: VectivBio Announces Closing of Comet Therapeutics Acquisition". Basel....
- [3] VectivBio Holding AG. (9/8/21). "Press Release: VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary". Basel....
- [4] VectivBio Holding AG. (8/31/21). "Press Release: VectivBio to Acquire Comet Therapeutics and Host R&D Day". Basel....
- [5] VectivBio Holding AG. (4/8/21). "Press Release: VectivBio Announces Pricing of Initial Public Offering". Basel....
- [6] VectivBio AG. (10/15/20). "Press Release: VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases". Basel....
- [7] VectivBio AG. (1/7/20). "Press Release: VectivBio Launches with $35M Financing to Bring Best-in-Disease Medicines to Patients with Serious Rare Diseases". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top